Castle Biosciences, Inc.
CSTL
$25.62
-$0.29-1.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -124.32% | -122.08% | -49.29% | -920.05% | 471.71% |
| Total Depreciation and Amortization | -34.52% | -559.87% | 1.97% | 791.14% | 78.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 63.97% | 66.62% | -55.45% | -6.51% | -31.65% |
| Change in Net Operating Assets | 604.44% | 1,382.35% | 345.08% | -8.43% | -74.13% |
| Cash from Operations | 10.53% | -3.03% | -13.24% | 11.69% | 31.09% |
| Capital Expenditure | 5.06% | -132.58% | -77.15% | 48.21% | -99.50% |
| Sale of Property, Plant, and Equipment | -28.57% | 375.00% | 500.00% | 80.00% | 133.33% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.11% | 57.53% | 97.52% | -67.71% | 443.38% |
| Cash from Investing | 53.05% | -24.34% | -32.50% | -13.86% | 175.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.85% | -29.17% | -181.82% | 27.78% | 27.78% |
| Issuance of Common Stock | 175.10% | -86.22% | -20.51% | -14.38% | 35.28% |
| Repurchase of Common Stock | -15.50% | 8.42% | 4.23% | -430.59% | -58.88% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 14.78% | -209.67% | 140.48% | -114.59% | -63.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.95% | -64.60% | -384.25% | -88.90% | 224.89% |